Edmonton, Alberta - CV Technologies (CDNX-CVQ) announces today that the U.S. Patent & Trademark Office has issued a Notice of Allowance for CV Technologies' proprietary product CVT-E002 patent application. This is the first allowed application, in a series of applications related to CVT-E002. The USPTO has allowed the claims for the process and composition of CVT-E002, with further claims pending.
CVT-E002 was developed by CV Technologies and has undergone several years of rigorous scientific testing. Including, the recently released double-blind, placebo-controlled U.S. FDA Phase II clinical trial, which indicated that use of CVT-E002, when compared to placebo, reduced the relative risk by 89% of developing laboratory confirmed influenza or Respiratory Syncytial Virus illness. The Natural Health Product form of CVT-E002, COLD-FXr, is currently sold across Canada through progressive retailers and health food stores.
According to Jackie Shan, CVT's Sr. Vice-President Research & Development, "Very few natural health products have been granted patent protection, because most applicants cannot demonstrate with precision the identity and functionality of active constituents. Utilizing CVT's proprietary ChemBioPrintT process (U.S. Patent No. 6,156,291) we are able to clearly define our product, both chemically and biologically. This has now led to the allowance of this patent application for our flagship product, CVT-E002, and the previous issuance of our patent for CVT-E001 (U.S. Patent 6,083,932)."
For more information about CV Technologies, Inc. please visit www.cvtechnologies.com
This news release contains forward-looking statements that involve risks and uncertainties, which may cause actual results to differ materially from the statements made. For this purpose, any statements that are contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words "believes", "anticipates", "plans", "intends", "expects" and similar expressions are intended to identify forward-looking statements. Such risks and uncertainties include, but are not limited to, the need for capital, changing market conditions, completion of clinical trials, patient enrollment rates, uncertainty of pre-clinical, retrospective and early clinical trial results, the establishment of manufacturing processes and new corporate alliances, the timely development, regulatory approval and market acceptance of the Company's products, and other risks detailed from time to time in the Company's filings with Canadia n securities authorities.